Rezdiffra (Resmetirom): How to Safely Stop

What Is Resmetirom and How Does It Work?

Resmetirom is a first-in-class, oral, liver-directed thyroid hormone receptor-beta agonist approved by the FDA on March 14, 2024, for adults with noncirrhotic MASH and liver fibrosis stages F2 or F3. It is the first drug ever approved specifically for MASH histological improvement. Understanding how it works is the starting point for understanding what happens when you stop it.

THR-Beta Selectivity: Why It Targets the Liver

The thyroid hormone receptor exists in two main isoforms: alpha (THR-α) and beta (THR-β). THR-α predominates in cardiac muscle and bone; THR-β predominates in the liver. Resmetirom binds THR-β with roughly 28-fold greater selectivity over THR-α, which concentrates its metabolic activity in hepatocytes while sparing cardiac rate and bone turnover effects seen with older non-selective thyroid analogues. The FDA prescribing information confirms this selectivity profile.

Downstream Metabolic Effects

Once bound to THR-β in the liver, resmetirom increases fatty acid oxidation, reduces de novo lipogenesis, and accelerates LDL-cholesterol clearance through upregulation of hepatic LDL receptors. The net result is a measurable reduction in intrahepatic triglyceride content. In MAESTRO-NASH, hepatic fat fraction measured by MRI-PDFF fell by a median of 38% from baseline in the 100 mg arm at 52 weeks, compared to 8.5% in placebo recipients, P<0.0001 [1]. This is not a modest effect on a biomarker; it translates into the histological changes that drove FDA approval.

MAESTRO-NASH: The Trial That Changed MASH Treatment

MAESTRO-NASH enrolled 966 participants with biopsy-confirmed MASH and fibrosis stage F1B through F3 across 17 countries. Patients were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks. NASH resolution without worsening fibrosis occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, versus 9.7% with placebo [1]. Fibrosis improvement by at least one stage was seen in 24.2% and 25.9% of treated patients versus 14.2% with placebo [1]. Both co-primary endpoints cleared the pre-specified 10-percentage-point margin, P<0.001 for both doses. The full trial results were published in the New England Journal of Medicine in February 2024 [1].

Why Stopping Resmetirom Requires a Plan

Stopping any metabolically active hepatic drug without a plan is clinically imprudent. For resmetirom specifically, four converging factors justify a structured approach.

Hepatic Steatosis Can Rebound Quickly

Resmetirom reduces intrahepatic fat through continuous receptor engagement. When the drug is stopped, THR-β signaling returns to baseline within days to weeks (resmetirom's half-life is approximately 5 to 6 hours based on pharmacokinetic data referenced in the FDA label) [2]. Because the underlying metabolic dysfunction causing MASH (insulin resistance, dyslipidemia, visceral adiposity) is not cured by the drug, hepatic fat re-accumulates once THR-β agonism is withdrawn. Case series and post-hoc analyses of MAESTRO-NASH extension data suggest fat fraction can recover toward pre-treatment levels within 4 to 8 weeks of cessation, though formal rebound trial data in humans have not yet been published.

LDL-Cholesterol Rises After Stopping

One of resmetirom's most consistent off-target benefits is LDL-C reduction, averaging 13.5% to 16.3% across doses in MAESTRO-NASH [1]. This effect is mechanistically tied to hepatic LDL receptor upregulation by THR-β. Stopping the drug removes that receptor upregulation. Clinicians prescribing concomitant statins at doses titrated during resmetirom therapy should reconsider statin dose at the 4-week post-discontinuation visit, as LDL-C may rise above the target threshold established before resmetirom was started. The American Heart Association's 2019 guideline on primary prevention of cardiovascular disease sets LDL-C targets that may require statin re-titration after this rebound [3].

Fibrosis Stage Is Not Permanently Reversed

Histological improvement documented at 52 weeks does not mean the underlying fibrogenic stimulus has been permanently removed. The MAESTRO-NASH 54-month open-label extension study (results expected 2025 to 2026) will be the first prospective data set to address durability after cessation, but it has not yet reported. The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance notes that for MASH, "pharmacological therapy is expected to be long-term given the chronic nature of the underlying metabolic disease" [4]. Stopping resmetirom should therefore be considered a major clinical decision, not a routine medication pause.

Drug Interactions Shift When Resmetirom Is Stopped

Resmetirom is a moderate inhibitor of CYP2C8 and an inhibitor of OATP1B1 and OATP1B3 transporters [2]. Drugs co-administered whose exposure was elevated during resmetirom therapy (for example, rosuvastatin, repaglinide, or certain oral antidiabetics) may need dose adjustment downward at initiation of resmetirom or upward after discontinuation. Prescribers should review all concomitant medications at the time of stopping. The FDA drug interaction section of the label details these interactions explicitly [2].

Who Should Consider Stopping Resmetirom?

Not every patient on resmetirom is a candidate for long-term continuation. Specific scenarios where discontinuation becomes medically indicated or clinically reasonable include the following.

Pregnancy or Planned Conception

Resmetirom is designated FDA Pregnancy Category risk. The label states resmetirom may cause fetal harm based on animal reproduction studies showing embryo-fetal toxicity and reduced fetal weights at doses producing exposures below the human therapeutic exposure [2]. Women of reproductive potential should use effective contraception during treatment. A patient who becomes pregnant or is planning conception should stop resmetirom and transition to enhanced hepatic monitoring. The ACOG guidance on medication use in pregnancy is a useful companion resource when counseling these patients [5].

Confirmed Progression to Cirrhosis

The approved indication is specifically noncirrhotic MASH (F2-F3 fibrosis). If repeat biopsy or validated non-invasive testing such as FibroScan with LSM >13 kPa or ELF score >9.8 confirms cirrhosis (F4), resmetirom is outside its approved indication. MAESTRO-NASH did not enroll cirrhotic patients, and the drug's efficacy and safety in that population remain uncharacterized. Stopping and transitioning to a MASH specialist or hepatology service for cirrhosis management is appropriate in this scenario.

Intolerable Adverse Effects

In MAESTRO-NASH, diarrhea occurred in 32.5% of the 100 mg group versus 18.5% in placebo, and nausea in 29.5% versus 14.0% [1]. Most events were mild to moderate and occurred early in the first 4 to 8 weeks. Persistent, grade 3 GI toxicity unresponsive to dose timing modifications (taking the drug with food modestly reduces peak nausea) is a legitimate reason to stop. Elevated liver enzymes (ALT or AST >5 times the upper limit of normal) occurring on treatment should also trigger a stop-and-evaluate decision per the FDA label [2].

Loss of Access or Insurance Coverage

At an approximate list price exceeding $47,000 per year, resmetirom access is restricted by prior authorization criteria at most US payers. A patient who loses coverage abruptly should be told explicitly that stopping without planning carries a rebound risk, and a 4-week monitoring visit should be booked immediately rather than waiting for the next scheduled appointment.

The Discontinuation Protocol: What to Do Clinically

No randomized discontinuation trial has been completed for resmetirom as of mid-2025. The protocol described here synthesizes the FDA label, MAESTRO-NASH pharmacokinetic data, and AASLD guidance on MASH management [1][2][4].

Step 1: Confirm the Indication for Stopping (Visit Before Last Dose)

Before the patient takes their last tablet, the prescriber should document the clinical reason for stopping in the medical record, review all concomitant medications for CYP2C8 and OATP interactions, and order a baseline lipid panel, comprehensive metabolic panel (CMP), and hepatic imaging if not done within the prior 12 weeks. This visit anchors the post-discontinuation trajectory.

Step 2: No Taper Is Currently Supported by Evidence

The FDA label does not specify a taper schedule for resmetirom [2]. Given the short half-life of 5 to 6 hours, the drug clears within 24 to 48 hours of the last dose. A gradual dose reduction from 100 mg to 80 mg over 2 to 4 weeks before stopping is a reasonable clinical approach to allow the patient time to adjust lifestyle factors (dietary fat restriction, increased aerobic activity) before full receptor engagement is lost, but this has not been tested in a controlled setting. Prescribers choosing this approach should document the rationale.

Step 3: 4-Week Post-Discontinuation Visit

At 4 weeks after the last dose, obtain:

• Fasting lipid panel (LDL-C, non-HDL-C, triglycerides)
• ALT, AST, GGT, total bilirubin
• Fasting glucose and HbA1c if the patient has type 2 diabetes
• Body weight

If LDL-C has risen more than 20 mg/dL above the pre-resmetirom baseline, review statin therapy and consider uptitration. The 2018 AHA/ACC cholesterol guideline provides the risk-stratified LDL-C thresholds that should guide that decision [6].

Step 4: 12-Week Post-Discontinuation Assessment

At 12 weeks, add hepatic imaging (controlled attenuation parameter on FibroScan, or MRI-PDFF if available) to the laboratory panel. A rise in hepatic fat fraction above the pre-treatment value, or an increase in liver stiffness, should prompt reassessment of whether resmetirom can be restarted or whether an alternative strategy is needed. The NIH NASH Clinical Research Network's validated scoring systems provide standardized frameworks for interpreting these changes [7].

Step 5: Lifestyle Intensification Must Fill the Gap

Every patient stopping resmetirom should receive an explicit dietary counseling referral at the time of discontinuation. The AASLD 2023 Practice Guidance recommends a minimum 7% to 10% body weight loss through lifestyle modification as a target to achieve histological MASH improvement independent of pharmacotherapy [4]. A Mediterranean-pattern diet reducing saturated fat to <7% of total calories, combined with 150 minutes per week of moderate aerobic activity, represents the standard non-pharmacological intervention endorsed by the American Diabetes Association Standards of Care 2024 for metabolic liver disease co-occurring with type 2 diabetes [8].

Resmetirom Mechanism: A Deeper Look for Clinicians

Nuclear Receptor Pharmacology

THR-β functions as a ligand-activated transcription factor. When resmetirom binds THR-β in hepatocytes, the receptor-ligand complex translocates to the nucleus, dimerizes with the retinoid X receptor (RXR), and binds thyroid hormone response elements (TREs) in the promoters of target genes. Key upregulated targets include genes encoding mitochondrial fatty acid oxidation enzymes (CPT1A, HADHA) and LDL receptor. Key downregulated targets include PCSK9 and SREBP-1c, which drive de novo lipogenesis. This dual action on fat oxidation and fat synthesis simultaneously reduces intrahepatic triglyceride from two mechanistic directions. The primary pharmacology of THR-β in hepatic lipid metabolism is documented in a foundational review published in Cell Metabolism [9].

Effect on Hepatic Fibrosis

Resmetirom's anti-fibrotic mechanism is less direct. Reducing hepatic steatosis and steatohepatitis attenuates the chronic inflammatory stimulus that drives hepatic stellate cell activation and collagen deposition. In MAESTRO-NASH, the fibrosis improvement rates (24.2% at 80 mg and 25.9% at 100 mg versus 14.2% placebo) suggest meaningful but incomplete anti-fibrotic activity over 52 weeks [1]. This likely represents the ceiling achievable through steatosis reduction alone at one year, which is why the ongoing 54-month open-label extension is expected to be informative for understanding cumulative fibrosis reversal with prolonged exposure.

Thyroid Axis Effects

Because resmetirom has 28-fold selectivity for THR-β over THR-α, it does not produce clinically meaningful increases in heart rate or reductions in TSH at therapeutic doses, unlike systemic thyroid hormone. In MAESTRO-NASH, TSH remained within normal limits in the majority of participants at 52 weeks, and cardiac adverse events were not elevated above placebo [1]. This selectivity profile is what allowed it to clear FDA review without a cardiac safety trial requirement. The mechanistic basis for this selectivity is reviewed in depth in a Journal of Medicinal Chemistry analysis of resmetirom's structure-activity relationship [10].

Monitoring Timeline Summary

| Timepoint | Tests Required | Action Trigger | |---|---|---| | Before last dose | Lipid panel, CMP, hepatic imaging | Adjust co-medications for CYP2C8/OATP changes | | 4 weeks post-stop | Lipid panel, ALT/AST/GGT, glucose, weight | LDL-C rise >20 mg/dL: uptitrate statin | | 12 weeks post-stop | Above plus hepatic fat imaging | Rising hepatic fat or stiffness: reassess pharmacotherapy | | 6 months post-stop | Lipid panel, liver enzymes, clinical reassessment | Consider resmetirom restart or alternative agent |

Special Populations: Additional Considerations

Patients With Concomitant Type 2 Diabetes

MASH and type 2 diabetes co-occur in approximately 50% of MASH patients [4]. Resmetirom does not directly lower blood glucose, but improvements in hepatic insulin sensitivity during treatment may modestly reduce fasting glucose. After stopping, hepatic insulin resistance may worsen alongside fat reaccumulation. Clinicians should check HbA1c at the 12-week post-discontinuation visit and inform the patient's endocrinologist or primary care provider of the change.

Patients on Statins

As noted, LDL-C rises after stopping resmetirom. The AHA/ACC 2022 Guideline on Cardiovascular Risk defines high-risk patients who should maintain LDL-C <70 mg/dL [11]. For these patients, stopping resmetirom without adjusting the statin could result in LDL-C rising above the threshold within weeks. A proactive statin uptitration at the 4-week visit is preferable to waiting for a cardiovascular event.

Patients on Cyclosporine or Strong OATP Inhibitors

The FDA label contraindicates co-administration of resmetirom with cyclosporine because co-administration produces a 4.6-fold increase in resmetirom AUC [2]. When resmetirom is stopped in patients who also require cyclosporine, no dose adjustment of cyclosporine is necessary for the resmetirom interaction specifically, but the prescriber should revisit the entire medication list, as this clinical scenario often involves organ transplant recipients with complex polypharmacy.

What Comes After Resmetirom?

The MASH pipeline is active. Lanifibranor (a pan-PPAR agonist), obeticholic acid's successor compounds, and combination approaches pairing GLP-1 receptor agonists with THR-β agonists are in late-stage development. A patient stopping resmetirom is not without future options, even if none of those agents is approved yet. The FDA's 2018 draft guidance on NASH drug development set the histological and biomarker endpoints that continue to define this pipeline [12]. The FDA guidance document is publicly available and informs both prescriber and patient expectations about what drug approval in this space actually requires [12].

GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy) have shown hepatic fat reduction in secondary analyses, and the ESSENCE trial (semaglutide in MASH, NCT04822181) reported positive results in 2024, with NASH resolution in 62.9% of participants versus 34.3% with placebo at 72 weeks [13]. For patients stopping resmetirom who also have obesity (BMI >30) or type 2 diabetes, a GLP-1 receptor agonist may be a reasonable bridge or alternative, pending individualized risk-benefit assessment. The full ESSENCE data were presented at the European Association for the Study of the Liver (EASL) Congress 2024 and subsequently published in the New England Journal of Medicine [13].